Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
life sciences
national blog main
9
×
new york blog main
9
×
boston blog main
boston top stories
national top stories
new york top stories
clinical trials
amgen
fda
san francisco blog main
san francisco top stories
startups
boston
deals
national
novartis
san diego blog main
san diego top stories
vc
alirocumab
alnylam pharmaceuticals
biogen
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
eli lilly
europe blog main
evolocumab
inclisiran
indiana blog main
indiana top stories
ipo
new york
pcsk9 inhibitors
ptc therapeutics
raleigh-durham blog main
What
medicines
9
×
new
9
×
fda
based
class
drug
aims
biotech
brings
cholesterol
deal
developing
drugs
formed
ipo
medco
migraine
nod
research
startup
acquire
activity
adults
agreed
aiming
allergan
alnylam
ambys
amgen
approach
approval
approvals
approved
backed
begin
big
billion
bio
biogen
biosciences
Language
unset
Current search:
medicines
×
biotech
×
" national blog main "
×
" new york blog main "
×
new
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines